Luyan Pharma Co.,Ltd. (002788.SZ)
CNY 8.03
(-0.5%)
CNY 8.03
(-0.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 468.55 Million CNY | -36.72% |
| 2022 | 740.43 Million CNY | 14.78% |
| 2021 | 645.08 Million CNY | 9.5% |
| 2020 | 589.09 Million CNY | 7.69% |
| 2019 | 547.01 Million CNY | 109.63% |
| 2018 | 260.93 Million CNY | 31.36% |
| 2017 | 198.64 Million CNY | 28.97% |
| 2016 | 154.02 Million CNY | 1.18% |
| 2015 | 152.22 Million CNY | 4.14% |
| 2014 | 146.18 Million CNY | 0.45% |
| 2013 | 145.52 Million CNY | 19.96% |
| 2012 | 121.31 Million CNY | 41.85% |
| 2011 | 85.52 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 105.52 Million CNY | -27.78% |
| 2024 Q2 | 191.77 Million CNY | 81.74% |
| 2024 Q3 | 91.97 Million CNY | -22.71% |
| 2023 Q2 | 131.22 Million CNY | 29.58% |
| 2023 Q4 | 146.1 Million CNY | 62.41% |
| 2023 FY | 468.55 Million CNY | -36.72% |
| 2023 Q3 | 89.96 Million CNY | -31.44% |
| 2023 Q1 | 101.26 Million CNY | -24.81% |
| 2022 Q3 | 107.13 Million CNY | -16.99% |
| 2022 FY | 740.43 Million CNY | 14.78% |
| 2022 Q4 | 134.68 Million CNY | 25.71% |
| 2022 Q2 | 129.06 Million CNY | 35.78% |
| 2022 Q1 | 95.05 Million CNY | -8.78% |
| 2021 FY | 645.08 Million CNY | 9.5% |
| 2021 Q3 | 100.55 Million CNY | -13.81% |
| 2021 Q4 | 104.2 Million CNY | 3.63% |
| 2021 Q2 | 116.67 Million CNY | 38.18% |
| 2021 Q1 | 84.43 Million CNY | 3.8% |
| 2020 Q3 | 111.62 Million CNY | -0.84% |
| 2020 Q2 | 112.56 Million CNY | 62.67% |
| 2020 FY | 589.09 Million CNY | 7.69% |
| 2020 Q1 | 69.19 Million CNY | -12.59% |
| 2020 Q4 | 81.34 Million CNY | -27.12% |
| 2019 Q3 | 96.29 Million CNY | -11.14% |
| 2019 FY | 547.01 Million CNY | 109.63% |
| 2019 Q2 | 108.36 Million CNY | 73.94% |
| 2019 Q1 | 62.3 Million CNY | -7.69% |
| 2019 Q4 | 79.16 Million CNY | -17.79% |
| 2018 Q2 | 61.54 Million CNY | 23.1% |
| 2018 Q4 | 67.49 Million CNY | -17.59% |
| 2018 FY | 260.93 Million CNY | 31.36% |
| 2018 Q3 | 81.9 Million CNY | 33.08% |
| 2018 Q1 | 49.99 Million CNY | -11.11% |
| 2017 Q1 | 31.53 Million CNY | -29.11% |
| 2017 FY | 198.64 Million CNY | 28.97% |
| 2017 Q3 | 51.99 Million CNY | -11.69% |
| 2017 Q4 | 56.24 Million CNY | 8.18% |
| 2017 Q2 | 58.87 Million CNY | 86.7% |
| 2016 Q1 | 29.71 Million CNY | -39.97% |
| 2016 Q2 | 46.85 Million CNY | 57.69% |
| 2016 Q4 | 44.48 Million CNY | 34.93% |
| 2016 FY | 154.02 Million CNY | 1.18% |
| 2016 Q3 | 32.97 Million CNY | -29.63% |
| 2015 Q4 | 49.49 Million CNY | 63.05% |
| 2015 Q1 | 28.25 Million CNY | 0.0% |
| 2015 Q3 | 30.35 Million CNY | -31.19% |
| 2015 FY | 152.22 Million CNY | 4.14% |
| 2015 Q2 | 44.11 Million CNY | 56.15% |
| 2014 FY | 146.18 Million CNY | 0.45% |
| 2013 FY | 145.52 Million CNY | 19.96% |
| 2012 FY | 121.31 Million CNY | 41.85% |
| 2011 FY | 85.52 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Cachet Pharmaceutical Co., Ltd. | 733.77 Million CNY | 36.144% |
| Yixintang Pharmaceutical Group Co., Ltd. | 786.44 Million CNY | 40.421% |
| ZJAMP Group Co., Ltd. | 1.05 Billion CNY | 55.429% |
| Ji Yao Holding Group Co., Ltd. | -346.79 Million CNY | 235.112% |